News and Events
Dr. Makriyannis and associates are first to crystalize the structure of the CB1 receptor (inactive receptor) (2016), CB1 (active receptor) (2017), and CB2 (inactive receptor) (2018). See the first three publications listed.
Recent Publications
To view click below
Crystal Structure Publications
Crystal Structures of Agonist-Bound Human Cannabinoid Receptor CB1
Crystal Structure of the Human Cannabinoid Receptor CB2
Crystal Structure of the Human Cannabinoid Receptor CB1
Publications for Addiction
CB1 receptor antagonism in the bed nucleus of the stria terminalis interferes with affective opioid withdrawal in rats.
Cannabinoid CB1 discrimination: effects of endocannabinoids and catabolic enzyme inhibitors.
Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling.
Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats
Blockade of nicotine and cannabinoid reinforcement and relapse by a cannabinoid CB1-receptor neutral antagonist AM4113 and inverse agonist rimonabant in squirrel monkeys.
Long-lasting in vivo effects of the cannabinoid CB1 antagonist AM6538.
PTSD Publications
Novel c-ring-hydroxy-substituted controlled deactivation cannabinergic analogues.
Endocannabinoid signaling regulates sleep stability.
A comparison of novel, selective fatty acid amide hydrolasse (FAAH) monoacyglycerol lipase (MAGL) or dual FAAH/MAGL inhibitors to suppress acute and anticipatory nausea in rat models.
IBD Publications
N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acelethanolamine levels and macrophage activation.
Inflammation and Pain Publications